Media Center
Press Releases
06 Sep 17

Back to posts

Global dermatology pipeline to see shift towards increased usage of biologics, says GBI Research

 The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of the pipeline dominated by generics and biosimilars, according to business intelligence provider GBI Research.

The company’s latest report: ‘Global Dermatology Drugs Market to 2023’ states that some 42% of the pipeline is in the Preclinical stage, while 14% is in the discovery stage and only 3% of drugs are in the Pre-registration stage. Around a third of the pipeline is in clinical development, and fewer than half are novel.

Ross Wilkinson, Associate Analyst for GBI Research, explains: “The strong presence of biologics in the late-stage pipeline could have a considerable impact on treatment algorithms in the dermatology therapy area over the forecast period. Furthermore, these innovative therapies, which have only been used for a little over a decade, in primarily a single dermatological indication, were able to reap large commercial revenues – as illustrated by the success of Humira and Stelara for the treatment of moderate-to-severe psoriasis – and will continue to do so with the expected shift towards increased usage of biologics.”

Overall, the dermatology pipeline is highly innovative, owing to advancements in understanding the disease pathways of many skin disorders. The majority of dermatology pipeline assets are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications. 

Wilkinson concludes: “As the phase of development progresses, the degree of novelty decreases.’’

According to GBI Research, 98% of products at the discovery phase are novel, and only 46% of pipeline products are novel at the Pre-registration stage, illustrating that the development of novel pipeline products confers a greater risk of failure.

Wilkinson adds: ‘‘Nonetheless, there are still a notable number of novel molecules in late-stage development, which is indicative of a strong pipeline.”

-ENDS-

NOTES TO EDITORS

 - Comments provided by Ross Wilkinson, Associate Analyst for GBI Research.

- Information based on GBI Research’s report: ‘Global Dermatology Drugs Market to 2023.’

This report reviews the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action. There is also a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at dermatology product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market. Together with market size predictions and in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

ABOUT GBI RESEARCH

GBI Research is a market-leading provider of business intelligence reports,offering actionable data and forecasts based on the insights of key industry leaders to ensure you stayup-to-date with the latest emerging trends in your markets.

For further details, please Contact Us.

Latest Press Releases

Close

Send this to a colleague

I have read and accept terms and conditions and privacy policy

Cancel